Javelin Medical

Filter Implant for Stroke Prevention

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in May 2012 by Ofer Yodfat and Guy Shinar, Javelin Medical operates with 11–50 employees. The company is developing a medical device for stroke prevention, currently available for individuals with atrial fibrillation through participation in the CAPTURE II study in several European countries.

Business overview

Javelin Medical is a Health Tech & Life Sciences company focused on developing medical devices for stroke prevention. Its core product, Vine, is a permanent filter designed for implantation in the carotid arteries to intercept blood clots and prevent strokes in individuals with abnormal heart rhythm (atrial fibrillation). The device is implanted through a thin needle in a short procedure and serves the healthcare industry, specifically targeting healthcare providers, doctors, clinics, and hospitals in the cardiology and neurology sectors.

Strategic signal

In May 2019, Javelin Medical's novel carotid filter for stroke prevention in atrial fibrillation was highlighted, signaling the company's focus on addressing a critical medical need. This indicates a strategic validation of their device's potential within the medical community and suggests ongoing clinical development and market entry efforts.

Log in to access full profile

Company Intelligence Q&A

What is Javelin Medical's primary focus?
Javelin Medical is focused on developing a medical device to prevent stroke in individuals with abnormal heart rhythm (atrial fibrillation).
What is the name of Javelin Medical's core product?
Javelin Medical's core product is Vine, a permanent filter designed for implantation in the carotid arteries.
When was Javelin Medical founded?
Javelin Medical was founded in May 2012.
Who are the founders of Javelin Medical?
Javelin Medical was co-founded by Ofer Yodfat and Guy Shinar.
In which regions is Javelin Medical's Vine device currently available?
The Vine device is currently available for individuals with atrial fibrillation through participation in the CAPTURE II study in several European countries.
Log in to access full profile